pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2021-31-3-304-310pulmo-2366Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESРаспространенность новой коронавирусной инфекции COVID-19 у пациентов, перенесших легочную эндартерэктомию (по данным одноцентрового регистра)Prevalence of new coronavirus infection COVID-19 in patients undergoing pulmonary thromboendarterectomy (data from a single-center registry)ЛогиноваИ. Ю.LoginovaI. Yu.

Логинова Ирина Юрьевна – к. б. н., старший научный сотрудник группы клинической физиологии Центра анестезиологии и реаниматологии

630055, Новосибирск, ул. Речкуновская, 15тел.: (383) 347-60-66

Irina Yu. Loginova, Candidate of Biology, Senior Researcher, Clinical Physiology Group, Anesthesiology and Intensive Care Center

ul. Rechkunovskaya 15, Novosibirsk, 630055tel.: (383) 347-60-66

i_loginova@meshalkin.ruКаменскаяО. В.KamenskayaO. V.

Каменская Оксана Васильевна – д. м. н., ведущий научный сотрудник группы клинической физиологии Центра анестезиологии и реаниматологии

630055, Новосибирск, ул. Речкуновская, 15тел.: (383) 347-60-66

Oksana V. Kamenskaya, Doctor of Medicine, Leading Researcher, Group of clinical physiology, Anesthesiology and Intensive Care Center

ul. Rechkunovskaya 15, Novosibirsk, 630055tel.: (383) 347-60-66

o_kamenskaya@meshalkin.ruКлинковаА. С.KlinkovaA. S.

Клинкова Ася Станиславовна – к. м. н., старший научный сотрудник группы клинической физиологии Центра анестезиологии и реаниматологии

630055, Новосибирск, ул. Речкуновская, 15тел.: (383) 347-60-66

Asya S. Klinkova, Candidate of Medicine, Senior Researcher, Group of clinical physiology, Anesthesiology and Intensive Care Center

ul. Rechkunovskaya 15, Novosibirsk, 630055tel.: (383) 347-60-66

a_klinkova@meshalkin.ruЛомиворотовВ. В.LomivorotovV. V.

Ломиворотов Владимир Владимирович – д. м. н., член-корр. Российской академии наук, руководитель Центра анестезиологии и реаниматологии

630055, Новосибирск, ул. Речкуновская, 15тел.: (383) 347-60-66

Vladimir V. Lomivorotov, Doctor of Medicine, Corresponding Member of Russian Academy of Sciences, Head of Anesthesiology and Intensive Care Center

ul. Rechkunovskaya 15, Novosibirsk, 630055tel.: (383) 347-60-66

vv_lomivorotov@meshalkin.ruЧернявскийА. М.ChernyavskyA. M.

Чернявский Александр Михайлович – д. м. н., профессор, директор

630055, Новосибирск, ул. Речкуновская, 15тел.: (383) 347-60-40

Alexander M. Chernyavsky, Doctor of Medicine, Professor, Director

ul. Rechkunovskaya 15, Novosibirsk, 630055tel.: (383) 347-60-40

a_cherniavsky@meshalkin.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution National Medical Research Center named after Academician E.N. Meshalkin, Ministry of Healthcare of Russian FederationRussian Federation202110062021313304310Copyright © Логинова И.Ю., Каменская О.В., Клинкова А.С., Ломиворотов В.В., Чернявский А.М., 20212021Логинова И.Ю., Каменская О.В., Клинкова А.С., Ломиворотов В.В., Чернявский А.М.Loginova I.Y., Kamenskaya O.V., Klinkova A.S., Lomivorotov V.V., Chernyavsky A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2366

Целью исследования явилась оценка распространенности и клинико-функциональных особенностей новой коронавирусной инфекции (COVID-19) у пациентов, перенесших легочную эндартерэктомию (ЛЭЭ), на примере одноцентрового регистра. Материал и методы. В исследование включены пациенты (n = 127) с хронической тромбоэмболической легочной гипертензией, перенесшие в период с января 2016 по март 2020 г. ЛЭЭ и состоявшие в группе диспансерного наблюдения. Срок наблюдения после хирургического вмешательства составил ≥ 6 мес. Проведена оценка распространенности COVID-19 и клинико-функциональных особенностей кардиореспираторной системы у обследованных пациентов. Результаты. Средний срок наблюдения после ЛЭЭ составил 2,5 ± 0,9 года. Летальность, не ассоциированная с COVID-19, за этот период составила 14 (11 %) случаев, среди остальных пациентов (n = 113) выявлено 5 случаев COVID-19. В 1 случае течение инфекционного заболевания было бессимптомным, в остальных – с типичной клинической симптоматикой и развитием двусторонней полисегментарной пневмонии. Случаев, при которых потребовалась искусственная вентиляция легких, и летальных исходов не зарегистрировано. Все пациенты, перенесшие ЛЭЭ, соблюдали рекомендации по приему антикоагулянтов и при наличии резидуальной легочной гипертензии получали специфическую терапию. Во время лечения COVID-19 коррекция терапии не требовалась. Заключение. Заболеваемость COVID-19 в группе пациентов, перенесших ЛЭЭ, составила 4,4 %, летальных исходов не зарегистрировано. При диспансерном наблюдении и своевременном информировании пациентов, перенесших ЛЭЭ, уровень заболеваемости и смертности от COVID-19 может не превышать таковой в общей популяции. Требуются дальнейшее изучение и оценка влияния на клиническую картину и исход COVID-19 при постоянном приеме антикоагулянтов и специфических препаратов для лечения легочной артериальной гипертензии.

Aim. To assess the prevalence and clinical and functional features of a new coronavirus infection (COVID-19) in patients who underwent pulmonary thromboendarterectomy (PTE) using data from a single-center registry. Methods. This study included 127 patients with chronic thromboembolic pulmonary hypertension who underwent PTE from January 2016 to March 2020 and were included in a follow-up group. The follow-up after surgery was 6 or more months. The prevalence of COVID-19 and clinical and functional properties of the cardiorespiratory system were assessed in the study group. Results. The average follow-up period after PTE in the study group was 2.5 ± 0.9 years. 14 (11%) deaths not associated with COVID-19 were reported during this period. 5 cases of COVID-19 were detected among the remaining 113 patients. In one case, the infection was asymptomatic, while other patients had the typical clinical symptoms and developed bilateral polysegmental pneumonia. No patients required mechanical ventilation or died of COVID-19. All patients who underwent PTE were compliant with anticoagulation therapy and PAH-specific therapy for residual pulmonary hypertension. No adjustment of PAH-specific and anticoagulation therapy was required during COVID-19. Conclusion. The prevalence of COVID-19 in patients who underwent PTE was 4.4%, no deaths were recorded. Outpatient follow-up and timely informing of patients undergoing PTE allow keeping the COVID-19 morbidity and mortality in the studied group at the general population level. Evaluation of the impact of chronic anticoagulants and PAH-specific therapy on the outcome of COVID-19 deserves further research.

COVID-19новая короновирусная инфекциялегочная эндартерэктомияантикоагулянтная терапияCOVID-19new coronavirus infectionpulmonary thromboendarterectomyanticoagulation therapyReferencesАвдеев С.Н., Царева Н.А., Мержоева З.М. и др. Практические рекомендации по кислородотерапии и респираторной поддержке пациентов с COVID-19 на дореанимационном этапе. Пульмонология. 2020; 30 (2): 151–163. DOI: 10.18093/0869-0189-2020-30-2-151-163.Avdeev S.N., Tsareva N.N., Merzhoeva Z.M. et al. [Practical guidance for oxygen treatment and respiratory support of patients with COVID-19 infection before admission to intensive care unit]. Pul’monologiya. 2020; 30 (2): 151–163. DOI: 10.18093/0869-0189-2020-30-2-151-163. (in Russian).World Health Organization. Coronavirus Disease 2019 (COVID-19). Situation Report – 189. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200727-covid-19-sitrep-189.pdf?sfvrsn=b93a6913_2 [Accessed: July 27, 2020].World Health Organization. Coronavirus Disease 2019 (COVID-19). Situation Report – 189. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200727-covid-19-sitrep-189.pdf?sfvrsn=b93a6913_2 [Accessed: July 27, 2020].Министерство здравоохранения Российской Федерации. Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2020). Доступно на: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062 [Дата обращения: 20.11.20].Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Version 9 (October 26, 2020). Availble at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062 [Assessed: 20.11.20] (in Russian).Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020; 30 (5): 688–699. DOI: 10.18093/0869-0189-2020-30-5-688-699.Bubnova M.G., Aronov D.M. [COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation]. Pul’monologiya. 2020; 30 (5): 688–699. DOI: 10.18093/0869-0189-2020-30-5-688-699. (in Russian).Nuche J., Segura de la Cal T., Jiménez López Guarch C. et al. Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension. Diagnostics. 2020; 10 (8): 548. DOI: 10.3390/diagnostics10080548.Nuche J., Segura de la Cal T., Jiménez López Guarch C. et al. Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension. Diagnostics. 2020; 10 (8): 548. DOI: 10.3390/diagnostics10080548.Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020; 75 (18): 2352–2371. DOI: 10.1016/j.jacc.2020.03.031.Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020; 75 (18): 2352–2371. DOI: 10.1016/j.jacc.2020.03.031.Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020; 41 (19): 1858. DOI: 10.1093/eurheartj/ehaa254.Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020; 41 (19): 1858. DOI: 10.1093/eurheartj/ehaa254.Magrone T., Magrone M., Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target – a perspective. Endocr. Metab. Immune Disord. Drug Targets. 2020; 20 (6): 807–811. DOI: 10.2174/1871530320666200427112902.Magrone T., Magrone M., Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target – a perspective. Endocr. Metab. Immune Disord. Drug Targets. 2020; 20 (6): 807–811. DOI: 10.2174/1871530320666200427112902.Humbert M., Guignabert C., Bonnet S. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019; 53 (1): 1801887. DOI: 10.1183/13993003.01887-2018.Humbert M., Guignabert C., Bonnet S. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019; 53 (1): 1801887. DOI: 10.1183/13993003.01887-2018.Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161: 105850. DOI: 10.1016/j.rmed.2019.105850.Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161: 105850. DOI: 10.1016/j.rmed.2019.105850.Чазова И.Е., Мартынюк Т.В. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (II часть). Терапевтический архив. 2016; 88 (10): 63–73. DOI: 10.17116/terarkh201688663-73.Chazova I.E., Martynyuk T.V. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2)]. Terapevticheskiy arkhiv. 2016; 88 (10): 63–73. DOI: 10.17116/terarkh201688663-73. (in Russian).Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 2015; 46 (6): 1855–1856. DOI: 10.1183/13993003.51032-2015.Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 2015; 46 (6): 1855–1856. DOI: 10.1183/13993003.51032-2015.Horn E.M., Chakinala M., Oudiz R. et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020; 10 (2): 2045894020922799. DOI: 10.1177/2045894020922799.Horn E.M., Chakinala M., Oudiz R. et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020; 10 (2): 2045894020922799. DOI: 10.1177/2045894020922799.Segura de la Cal T., Nuche J., Jiménez López-Guarch C. et al. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020; 56 (11): 749–752. DOI: 10.1016/j.arbres.2020.06.004 (in English, Spanish).Segura de la Cal T., Nuche J., Jiménez López-Guarch C. et al. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020; 56 (11): 749–752. DOI: 10.1016/j.arbres.2020.06.004 (in English, Spanish).Sardu C., Gambardella J., Morelli M.B. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020; 9 (5): 1417. DOI: 10.3390/jcm9051417.Sardu C., Gambardella J., Morelli M.B. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020; 9 (5): 1417. DOI: 10.3390/jcm9051417.Smeda M., Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc. Res. 2020; 116 (10): e118–121. DOI: 10.1093/cvr/cvaa190.Smeda M., Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc. Res. 2020; 116 (10): e118–121. DOI: 10.1093/cvr/cvaa190.Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020; 41 (19): 1798–1800. DOI: 10.1093/eurheartj/ehaa231.Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020; 41 (19): 1798–1800. DOI: 10.1093/eurheartj/ehaa231.Cooper L.T. Jr. Myocarditis. N. Engl. J. Med. 2009; 360 (15): 1526-1538. DOI: 10.1056/NEJMra0800028.Cooper L.T. Jr. Myocarditis. N. Engl. J. Med. 2009; 360 (15): 1526-1538. DOI: 10.1056/NEJMra0800028.Levy J., Léotard A., Lawrence C. et al. A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments following severe COVID-19. Ann. Phys. Rehabil. Med. 2020; 63 (4): 376–378. DOI: 10.1016/j.rehab.2020.04.002.Levy J., Léotard A., Lawrence C. et al. A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments following severe COVID-19. Ann. Phys. Rehabil. Med. 2020; 63 (4): 376–378. DOI: 10.1016/j.rehab.2020.04.002.Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI: 10.1016/S2213-2600(20)30079-5.Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI: 10.1016/S2213-2600(20)30079-5.Carfì A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.Carfì A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.Mo X., Jian W., Su Z. et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020; 55 (6): 2001217. DOI: 10.1183/13993003.01217-2020.Mo X., Jian W., Su Z. et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020; 55 (6): 2001217. DOI: 10.1183/13993003.01217-2020.Patelli G., Paganoni S., Besana F. et al. Preliminary detection of lung hypoperfusion in discharged COVID-19 patients during recovery. Eur. J. Radiol. 2020; 129: 109121. DOI: 10.1016/j.ejrad.2020.109121.Patelli G., Paganoni S., Besana F. et al. Preliminary detection of lung hypoperfusion in discharged COVID-19 patients during recovery. Eur. J. Radiol. 2020; 129: 109121. DOI: 10.1016/j.ejrad.2020.109121.Becker R.C. COVID-19 update: COVID-19-associated coagulopathy. J. Thrombosis Thrombolysis. 2020; 50 (1): 54–67. DOI: 10.1007/s11239-020-02134-3.Becker R.C. COVID-19 update: COVID-19-associated coagulopathy. J. Thrombosis Thrombolysis. 2020; 50 (1): 54–67. DOI: 10.1007/s11239-020-02134-3.

The authors declare that there are no conflicts of interest present.